Výsledky vyhledávání - "Maria Patricia, Ganado"

Akademický článek

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy

Publikováno v: npj Breast Cancer, Vol 8, Iss 1, Pp 1-11 (2022)

Abstract Despite the biological and therapeutic relevance of CDK4/6 for the treatment of HR+, HER2- advanced breast cancer, the detailed mode of action of CDK4/6 inhibitors is not completely understood. Of particular interest, phosphorylation of CDK4

Externí odkaz: https://doaj.org/article/a4901c8cc1f2445081034949720c4383

Zobrazit plný text záznamu

Akademický článek

Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy

Publikováno v: npj Breast Cancer, Vol 8, Iss 1, Pp 1-2 (2022)

Externí odkaz: https://doaj.org/article/3b011c3c5bd0459a9b47a137f7b7d6fd

Zobrazit plný text záznamu

Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation

Autor: Raquel, Torres-Guzmán, Maria Patricia, Ganado, Cecilia, Mur, Carlos, Marugan, Carmen, Baquero, Yanzhu, Yang, Yi, Zeng, Huimin, Bian, Jian, Du, Alfonso, de Dios, Oscar, Puig, María José, Lallena

Publikováno v: Oncotarget. 13:864-875

Abemaciclib is an oral, selective cyclin-dependent kinase 46 inhibitor (CDK46i), approved for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) as monotherapy for endocrine refract

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69dab28f3ef5a47efbcef09588aa74ec
https://doi.org/10.18632/oncotarget.28249

Zobrazit plný text záznamu

Efficient inhibition of cell proliferation and promotion of apoptosis requires continuous treatment with abemaciclib

Autor: Raquel Torres-Guzmán, Carmen Baquero, Alfonso De Dios, Yi Zeng, Maria Jose Lallena, Maria Patricia Ganado, Cecilia Mur, Carlos Marugán, Yanzhu Yang, Oscar Puig, Jian Du, Huimin Bian

Abemaciclib is an oral, selective cyclin-dependent kinase 4 & 6 inhibitor (CDK4 & 6i), approved for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) as monotherapy for endocrine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ddd2ccf15e36d11d977f8cb9e51129e
https://doi.org/10.1101/2021.11.15.468648

Zobrazit plný text záznamu

Abemaciclib, a CDK4 and 6 inhibitor with unique pharmacological properties for breast cancer therapy

Autor: Jian Du, Carmen Baquero, Raquel Torres-Guzmán, Cecila Mur Pérez, Alfonso De Dios, Maria Jose Lallena, Maria Patricia Ganado, Yanzhu Yang, Carlos Marugán, Oscar Puig

Publikováno v: Journal of Clinical Oncology. 39:e12506-e12506

e12506 Background: Breast cancer is the second most common cancer worldwide. Pharmacologically targeting cyclin-dependent kinases 4 and 6 (CDK4 & 6) has proven to be a successful therapeutic approach in patients with estrogen receptor positive (ER+)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f981eda4189451f7722c83d732b899bb
https://doi.org/10.1200/jco.2021.39.15_suppl.e12506

Zobrazit plný text záznamu

Abstract 4850: Targeting prostate cancer with the CDK4 and CDK6 inhibitor abemaciclib

Autor: Jian Du, Carlos Marugán, Raquel Torres-Guzmán, Maria Patricia Ganado, Huimin Bian, Maria Jose Lallena, Carmen Baquero, Ramón Rama, Yi Zeng

Publikováno v: Cancer Research. 80:4850-4850

Background: Prostate cancer (PCa) is a leading cause of cancer death in men and represents a substantial public health burden [1]. Most PCa are primarily dependent on androgen receptor (AR) activity and castration is an effective approach to treat PC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b8d03bbdd69e7eb08cd4344f4a0e0b7f
https://doi.org/10.1158/1538-7445.am2020-4850

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání